Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who were diagnosed with AMI, including STEMI and NSTEMI, and underwent successful PCI and routine follow-up coronary angiography at the Second Affiliated Hospital of Zhejiang University School of Medicine between June 1, 2017 and May 31, 2020.~Exclusion Criteria:~* 1) prior treatment with any P2Y12 inhibitor;~* 2) need for long-term oral anticoagulation therapy;~* 3) previous coronary artery bypass grafting (CABG);~* 4) chronic renal dysfunction with estimated glomerular filtration rate (eGFR) \<30 mL/ (min·1.73 m2) or on hemodialysis;~* 5) liver cirrhosis ≥Child-Pugh B class;~* 6) cancer;~* 7) adjustment of dual antiplatelet therapy (DAPT) during follow-up;~* 8) inadequate coronary angiographic images.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Study Arms:
- ticagrelor maintenance treatment group (Type: None): Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and ticagrelor 90mg twice daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
- clopidogrel maintenance treatment group (Type: None): Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and clopidogrel 75mg once daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.

Based on this trial design, predict the completion outcome and termination type (if applicable).